Biomarkers and therapies associated with Hutchinson-Gilford Progeria Syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary empirical data
PubMed 42309396 · doi:10.1016/j.arr.2026.103209
What was done
The authors summarized current evidence on biomarker categories, preclinical translational models (progeroid mice and LMNA-edited minipigs), and therapeutic strategies for Hutchinson-Gilford progeria syndrome (HGPS), a premature aging disorder driven by progerin accumulation from LMNA mutations.
What was found
The abstract reports no numerical data or quantitative effect sizes. It details four candidate biomarker axes: molecular markers (LMNA genotype, progerin levels, DNA damage signaling, telomere shortening, epigenetic marks), cellular markers (oxidative stress, mitochondrial impairment, SASP), systemic inflammatory mediators, and vascular functional measures (arterial stiffness, endothelial dysfunction). It notes that while lonafarnib improves vascular outcomes and survival, emerging modalities such as mTOR modulators, senolytics, antisense oligonucleotides, and gene editing are needed to address persistent cardiovascular decline.
Why it matters
It outlines a framework for integrating multi-parameter biomarker panels into preclinical validation and clinical trial design for an ultra-rare, fatal disorder.
Limits
As a narrative review, the paper presents no original experimental data, quantitative synthesis, or systematic search protocol. No participant sample sizes, study counts, or quantitative outcome measures are provided in the abstract.
Cited by
- supports Hutchinson-Gilford progeria syndrome is characterized by the accumulation of progerin, a mutant lamin protein carrying a persistent farnesyl tag.